SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third-quarter report and managements upbeat 2027 outlook have driven CLFs sharp rally, with bullish traders focused on improved steel pricing and possible short covering. Others question whether the outlook can overcome the companys debt and execution concerns, and some view the move as a sell-the-news bounce.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy after a sharp selloff fueled hopes of a rebound, but traders debated whether the upgrade could overcome ongoing financing concerns, especially as the rally faded. Bulls point to AI demand, customer commitments and Nvidias support, while bears remain focused on CoreWeaves heavy debt burden and borrowing costs.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The FDAs early expansion of ANKTIVA plus BCG to papillary-only BCG-unresponsive bladder cancer, alongside long-term data showing durable responses, is driving discussion about a larger patient market and future sales. Traders are puzzled by the share-price decline despite the positive developments, debating a sell-the-news reaction and broader biotech weakness versus unverified claims of short-selling or options-related pressure.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under heavy pressure amid IPO lockup-related selling concerns and a broader AI and semiconductor pullback, with traders also questioning the companys valuation, growth, and ability to scale. Bears expect further downside as more shares become eligible for sale, while bulls view the selloff as excessive and are averaging in.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are under pressure amid a sharp pullback, with traders pointing to repeated insider sales and a reported DBS downgrade as potential reasons for the weakness; some also cite broader Indonesia and Southeast Asia market concerns. Bulls argue the selling was planned and the business remains strong, while bears see insider selling and weak price action as warning signs.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons advance is drawing attention after Morgan Stanley named it a top pick, citing AWS growth, AI opportunities and warehouse automation as potential catalysts. Traders are broadly bullish on the move, though some remain cautious about heavy AI spending and whether the shares can sustain gains ahead of earnings.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are broadly reacting positively, while debating short-squeeze potential and flagging dizziness and sharp price swings as concerns.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Sharp post-IPO selling and volatile trading dominate the discussion, with traders pointing to lockup-related supply, bearish analyst coverage, and weakness across nuclear stocks as possible pressures. Bulls are treating the pullback as an opportunity, citing Amazons backing and X-energys potential role in meeting future data-center power demand, while others stress that reactor commercialization remains years away.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff alongside other AI neocloud stocks, as traders debate financing costs and whether the sectors growth can justify its heavy capital needs. Some see the rebound and analyst support as a buying opportunity, while others call it a short-lived bounce and expect more pressure.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on the FDA-cleared expansion of Alpha Taus REGAIN trial for recurrent glioblastoma and anticipated clinical data at the SNO meeting. Traders are bullish on early tumor-control findings and the broader pipeline, though some note the evidence comes from a small initial cohort.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zydus Wellness targets $500 million face wash market with tan removal launch

The product is clinically tested across Indian skin types and combines chocolate’s antioxidant properties with Vitamin C-rich cherry extract

Zydus Wellness taps Milind Soman as brand ambassador for Glucon-D recharge

Zydus Wellness has appointed actor Milind Soman as the brand ambassador for its new product, Glucon-D Recharge. This marks the company's entry into the performance hydration category. Glucon-D Recharge is designed to help Indians stay active consistently. The product is available in ready-to-drink bottles and sachet sticks. This expansion caters to evolving consumer needs beyond traditional energy powders.

Whey protein sachets boost mass market reach

Mumbai: Once sold in bulky tubs mostly to bodybuilders, whey protein is now showing up in sachets and single scoop packs as marketers emulate the playbook of everyday fast-moving consumer goods (FMCG) to drive penetration, affordability and on-the-go consumption amid rising demand."Everyone is becoming more aware of how short on protein they are," said Tarun Arora, chief executive officer of Zydus Wellness. This is pushing protein from a discretionary purchase toward a lifestyle staple.However, high costs, driven by expensive raw materials and supply chains, have historically kept the category out of reach for many, with kilogram packs often priced above ₹2,000. Hence the small packs, which are cheaper to try and easier to carry. 129738045 "Sachets should be a growth mechanism, not a margin lever. It is about lowering friction, not lowering price," Arora said.Companies such as Truebasics, MuscleBlaze, Wellbeing Nutrition and Optimum Nutrition now offer sachet bundles priced between ₹699 and ₹999, compared with ₹3,499-₹4,429 for 1-kg tubs.While sachets lower upfront costs, the per-gram price of protein can be up to 40% higher than bulk formats.

Brief India: GR Infraprojects Ltd - Robust Order Book To Drive Growth; Retain BUY and more

In this briefing: GR Infraprojects Ltd - Robust Order Book To Drive Growth; Retain BUY Aurobindo Pharma Ltd - Operational Beat Sansera Engineering Ltd - ADS Growth Momentum & Capacity Expansion to Drive Visibility Event Driven: Edelweiss ~ How Housing Finance Stake Sale Unlocks Value? Primer: Zydus Wellness (ZYWL IN) - Feb 2026 1. GR Infraprojects Ltd - Robust Order Book To Drive Growth; Retain BUY Strong & Well-diversified Order Book Ensuring Revenue Visibility: The company’s order book position, including L1 projects, stands at Rs 24,965 Cr, comprising Roads, Railways, Transmission, Telecom/Optical Fibre, and Tunnel works, providing healthy revenue visibility for the next 24–36 months. A pick up in revenue is due to the oil & gas sector, and it is expected to contribute further Rs 1,000 Cr in FY27. We expect revenue to grow at 17% CAGR over FY25–FY27E. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Event Driven: Edelweiss ~ How Housing Finance Stake Sale Unlocks Value? and more

In this briefing: Event Driven: Edelweiss ~ How Housing Finance Stake Sale Unlocks Value? Primer: Zydus Wellness (ZYWL IN) - Feb 2026 Lucror Analytics - Morning Views Asia Aequitas: JSW Cement IPO Lockup Expiry - US$180m Lockup Release, But Shares Have Traded Down Aditya Birla Capital (ABCAP IN): Global Index Inclusion & Big Impact 1. Event Driven: Edelweiss ~ How Housing Finance Stake Sale Unlocks Value? Edelweiss Financial Services (EDEL IN) is divesting a controlling 73% stake in Nido Home Finance to Carlyle Group and Aditya Puri for approximately INR 2,100 crore The transaction infuses INR 1,500 crore capital into Nido for growth while providing liquidity to Edelweiss for reducing corporate debt and strengthening its balance sheet This strategic move unlocks significant value by monetizing a mature asset at a premium valuation while pivoting the group towards an asset-light business model 2. Primer: Zydus Wellness (ZYWL IN) - Feb 2026 Zydus Wellness holds a dominant market position in several of its core product categories, including a near-monopoly in the sugar substitute market with 'Sugar Free' holding a 95.9% share, and a leading position in the glucose powder segment with 'Glucon-D' at 58.8%.

Indian Equities Decline In Choppy Trade; SEBI RAs See Rangebound Session Despite GST Boost

Equity

Nifty gave up early gains on Friday, with IT and FMCG stocks dragging benchmark indices

Zydus Wellness Shares Extend Gains, But SEBI Analyst Sees Growth With Caution

The analyst rated the stock 7.3/10, noting steady sales growth but warning that volatile margins and profits make long-term visibility uncertain.

Nifty Reclaims 24,600 Led By Buying In Auto, IT Stocks; Midcaps & Smallcaps Outperform

Zydus Wellness jumped 11% on an overseas acquisition, while PG Electroplast gained on a new manufacturing MoU. Broader market momentum supported the rally.


Zydus Wellness Makes First Global Buy, Acquires UK’s Comfort Click For £239 Million

The acquisition will mark Zydus’ foray into the fast-growing vitamins, minerals, and supplements (VMS) market. 

Nifty Tops 24,500 As Strong GDP Data Lifts Market Sentiment; Midcaps, Smallcaps Shine

Analysts remain watchful of resistance zones despite the strong start, while retail sentiment remains ‘bearish’ on Stocktwits.


Zydus Wellness Ltd. engages in the business of development, production, marketing, and distribution of health and wellness products. The firm markets its products under the following brand names: Sugar free, Complan, Glucon-D, Everyuth, Nycil, and Nutralite. The company was founded in 1994 and is headquartered in Ahmedabad, India.

Zydus Wellness Ltd

Neutral Sentiment

Indian equities opened higher on Friday before paring all gains to decline within the first hour of trade. Sentiment on Dalal Street remained cautious after Thursday’s late selloff driven by profit booking.The benchmark indices rose by as much as 1% in the previous session, with heavy buying in consumer goods and auto stocks following the GST Council's approval of rate cuts in more than 175 product categories. However, the Nifty 50 index closed nearly unchanged while the Sensex gained 0.19%.Gains in auto stocks today were offset by losses across multiple sectors, primarily FMGC and IT.At 10:15 a.m. IST, the&nbsp;<a href="https://stocktwits.com/symbol/NIFTY50.NSE">Nifty 50</a> was trading at 24,677.55, while the Sensex fell to 80,496.36. Broader markets were mixed, with the Nifty Midcap index falling 0.02% and the Smallcap index trading 0.2% higher.However, retail sentiment for the Nifty 50 turned ‘bullish’ on Stocktwits. It was ‘neutral’ a day earlier.Stocks In FocusTwo-thirds of the stocks in the FMCG sector declined in early trade. ITC’s stock was down 2.2%, Emami’s shares shed 2.1%, while Marico and Nestle India fell 0.7% each.Every stock in the Nifty IT index fell, with heavyweights Tata Consultancy Services (TCS) and Infosys losing over 2% each. Mphasis was the biggest laggard on the index, declining 3.3%.Among the gainers, every stock in the Nifty Auto index was trading higher, led by Mahindra &amp; Mahindra (+2.05%), Exide Industries (+1.92%), and Ashok Leyland (+1.8%). Carmakers Maruti Suzuki and Tata Motors were trading up 1.34% and 1.28%, respectively.Zydus Life Sciences was up 2.5% after its unit Zydus Lifesciences Global FZE signed an exclusive licensing and supply deal with Synthon to supply a sclerosis drug.Analysts’ TakesThe market’s reaction to the GST rate cut has been puzzling. While most expected it to be positive, the day’s decline after a gap-up opening raises doubts, said SEBI RA&nbsp;<a href="https://stocktwits.com/BHARATSHARMA_StockAce_RA">Bharat Sharma</a>.<stembedurl>https://stocktwits.com/BHARATSHARMA_StockAce_RA/message/627487910</stembedurl>Normally, some profit booking is acceptable, but the lack of recovery suggests deeper concerns. If every sector remains weak, it hints that the GST cut decision may have underlying factors not fully understood yet, Sharma said.Technically, the market closed below the negative trendline again, so the broader view and strategy remain unchanged.For intraday, support is placed at 24,700, and a breakdown could push levels towards 24,650 - 24,600 - 24,560, while resistance stands at 24,770, with a move above that opening room for 24,840, 24,920, and 25,000, respectively, the analyst added.For intraday trading, the Nifty faces resistance in the 24,738-24,800 band and has support between 24,461 and 24,490, according to SEBI RA&nbsp;<a href="https://stocktwits.com/aymr_sebi_ra">A&amp;Y Market Research</a>.Bank Nifty’s resistance lies between 54,177 and 54,248, while support is placed between 53,495 and 53,660, they added.<stembedurl>https://stocktwits.com/aymr_sebi_ra/message/627581871</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An LED screen displays news of a tariff imposed by US President Donald Trump outside the Bombay Stock Exchange (BSE) building in Mumbai. (Photo by Ashish Vaishnav/SOPA Images/LightRocket via Getty Images)

Current Price	516.00
Prev Close	515.00
Open	511.55
Dividend Yield	0.28%
50-Day Moving Average	519.39
Beta	0.05
Avg. Volume	569,960.67
PE Ratio	86.68

52-Week High	611.85
52-Week Low	367.55
Market Capitalization	163.03B
EPS (Annual)	6.20
Price to Book	2.80
Revenue Per Employee	10.43M

Feed

News

Sentiment

Fundamentals

Info

ZYDUSWELL.NSE Fundamentals